Abstract: Non-alcoholic steatohepatitis (NASH) is an important step in the progress of steatosis development to liver cirrhosis, which is an important issue of global public health and gradually becoming the world’s leading cause of chronic liver disease. According to the relevant reports, diet and lifestyle measures as a first-line therapy for NASH are hardly a model of successful therapy and of limited efficacy in advanced stages of the disease. Recently, people have realized the necessity of specific drug therapeutics. This paper reviews the drugs available currently and those in the clinical trials on the market, to provide the NASH researchers or experts in the relevant field with the information of the latest research progress.